Drug Profile


Alternative Names: ATL 146e; BMS 068645; Stedivaze

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Virginia
  • Developer Adenosine Therapeutics; Forest Laboratories
  • Class Alkynes; Contrast media; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Coronary disorders
  • Discontinued Coronary artery restenosis; Inflammation; Inflammatory bowel diseases; Reperfusion injury; Septic shock; Spinal cord injuries

Most Recent Events

  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 31 Dec 2012 Adenosine Therapeutics reacquires an exclusive worldwide licence to apadenoson
  • 30 Apr 2012 Suspended - Phase-III for Coronary disorders (diagnosis) in Argentina (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top